Spiriva Respimat Approved for maintenance of COPD
"Boehringer Ingelheim announced that the US regulatory body has approved Spiriva Respimat (tiotropium bromide) inhalation spray for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)." According to the Pharmaceutical Journal, Spiriva Respimat (tiotropium bromide monohydrate; Boehringer Ingelheim) is now recommended as an add-on preventive therapy. It is for adult asthma patients currently being treated with a maintenance combination of inhaled corticosteroids and long-acting β2 agonists who already had one or more serious exacerbations in the previous year. Spiriva Respimat releases a pre-measured dosage in a slow-moving spray, irrespective of how easily air from the inhaler is breathed in. The Respimat inhaler creates the slow-moving mist through mechanical energy. Spiriva Respimat solution uses the same element as Spiriva HandiHaler (inhalation material for tiotropium bromide) as stated by MPR